I was in an Apple Inc. store this weekend, and there is huge interest in the watch. Consumers will be able to demo the watch on April 10, and that is when Apple Inc. will be taking pre-orders. We will soon know about the demand for the watch. I am thinking it will be similar to the iPad. However, it will not be like the iPhone. The watch will add just one more revenue stream for Apple Inc.
The latest Newsweek has an article painting a grim picture for California water supply. There is only one year of water left in the California water supply. Here is a quote from NASA….
"Plagued by prolonged drought, California now has only enough water to get it through the next year, according to NASA."
AAPL will have another blowout EPS report next month, and then long lines for the watch on April 24. All one needs to do is hold, and add on dips. Pretty simple stuff.
Yes, California is in a severe drought, and water is a precious commodity. The rainfall this year was actually a bit better than the past three years. However, it is not nearly enough to satisfy the water needs of the state.
AWR is already sporting a pretty rich premium for a utility company at 25. I am long, and would be happy if the stock hovers around $40-$45 this year
Yes! I am buying the watch on April 24. I like the Apple Pay function and the health aspects of the watch.I bet they sell 20 million in the first quarter the new product is on the market.
Well, that did not last very long! AWR popped well above its 10 week line today. The stock was under the key technical level for a grand total of four days. This stock is showing strength because of its balance sheet, solid earnings, and increasing dividend.
I sold all my shares as I cannot let a profit turn into a loss. I do not trust this management team either. The shorts are in control here, and ACAD is likely to have another earnings miss this quarter.
ACAD is a speculative stock. Congrats if you bought in under $20 as I believe you are safe for now.
The stock is down 25% on massive volume, and that is a recipe for more downside ahead.
Some drug companies can bring drug after drug through their pipeline, and get them approved in a timely manner. Others (like ACAD) cannot make the same claim. The ongoing delays for bringing this sone drug to market is bothersome. I believe the stock price is still too high based on their past earnings history and inability to execute on their pipeline.
Speculative stocks like ACAD sometimes get haircuts of 25% or more for their inability to execute. Maybe CELG would be abetter buy if you want to own biotech? That firm knows how to execute!
I hit him up on Twiiter with no reply. If the stock went up 22% he would take a victory lap.
Now the stock has cratered, he goes silent and hopes nobody notices he supported this equity.
The stock is down 22% on massive volume. The shorts may like this action? But, as I long I find it destructive to my portfolio. I bout at $27, and this action has severely cut into profits.
Canning the CEO is a positive action moving forward. The delay is not, and that is a problem. ACAD continues to delay their drug, and Wall Street does not trust their management team. The uncertainty is a big problem for Wall Street. The stock may trade in a range of $32-$36 for a while?
The execution by ACAD management has been poor. The CEO was shown the door. Perhaps the new CEO has a clue?
There is a ton of M&A in this sector right now. There is no reason to think ACAD will not be a part of the consolidation in this space.
Even with an earnings miss the stock did not flinch. Now, the firm will either have a successful drug or a buyout, or both! The shorts cannot win here. All longs need to do is hold and buy dips. This squeeze will take time to unwind.